Rational therapeutic intervention in cancer: Kinases as drug targets

Current Opinion in Genetics and Development

Volumn 12, Issue 1, 2002, Pages 111-115

  Sawyers, Charles L ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 DIMETHYL 5 (2 OXO 1H INDOL 3 YLMETHYLENE) 3 PYRROLEPROPIONIC ACID; 6 (4 HYDROXYPHENYL) 4 (ALPHA METHYLBENZYLAMINO) 7H PYRROLO[2,3 D]PYRIMIDINE; BCR ABL PROTEIN; CETUXIMAB; ERLOTINIB; GEFITINIB; IMATINIB; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY MDX 447; MONOCLONAL ANTIBODY MDX H210; PERTUZUMAB; PLATELET DERIVED GROWTH FACTOR RECEPTOR; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE KINASE INHIBITOR; SEMAXANIB; STEM CELL FACTOR RECEPTOR; TRASTUZUMAB; UNCLASSIFIED DRUG; VATALANIB;

BREAST CANCER; CANCER CHEMOTHERAPY; CANCER RESEARCH; CANCER SURVIVAL; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; DRUG EFFECT; DRUG RESPONSE; DRUG TARGETING; ENZYME INHIBITION; GASTROINTESTINAL TUMOR; HUMAN; METASTASIS; ONCOGENE NEU; PRIORITY JOURNAL; REVIEW;

EID: 0036467568     PISSN: 0959437X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-437X(01)00273-8     Document Type: Review

References (37)

1. Structural mechanism for STI-571 inhibition of abelson tyrosine kinase
2. Down-modulation of an oncogene protein product and reversion of the transformed phenotype by monoclonal antibodies
3. Nonclinical studies addressing the mechanism of action of trastuzumab (Herceptin)
4. Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets
5. HER-2/neu oncogene amplification and expression in breast and ovarian cancers
6. Chronic myeloid leukemia
7. Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogene
8. Stochastic appearance of mammary tumors in transgenic mice carrying the MMTV/c-neu oncogene
9. Inhibition of tumor growth by a monoclonal antibody reactive with an oncogene-encoded tumor antigen
10. Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer
11. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease
12. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2
13. Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative
14. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells
15. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia
16. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome
17. Glivec™ (imatinib mesylate) induces hematologic and cytogenetic responses in the majority of patients with chronic myeloid leukemia: Results of a phase II study
18. Glivec™ (imatinib mesylate) induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: Results of a phase II study
19. Glivec™ (imatinib mesylate) induces hematologic and cytogenetic responses in patients with chronic myeloid leukemia in myeloid blast crisis: Results of a phase II study
20. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification
21. Molecular and chromosomal mechanisms of resistance in CML patients after STI571 (Glivec) therapy
22. Point mutations clustered within the ATP binding region of BCR-ABL are common in patients with emerging Glivec resistance but not in Glivec non-responsive cases of CML
23. Different BCR-ABL gene mutations can cause clinical resistance of Philadelphia-positive leukemia towards STI571
24. Resistance to Gleevec: Sequence analysis reveals a spectrum of BCR/ABL kinase domain mutations in both acquired and de novo-resistant cases of CML in myeloid blast crisis
25. Roots of clinical resistance to STI-571 cancer therapy
26. Roots of clinical resistance to STI-571 cancer therapy
27. Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor
28. Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: A phase I study
29. Evaluation of the safety and efficacy of an oral molecularly-targeted therapy, STI571, in patients (Pts) with unresectable or metastatic gastrointestinal stromal tumors (GISTS) expressing C-KIT (CD117)
30. Fusion of PDGF receptor beta to a novel ets-like gene, tel, in chronic myelomonocytic leukemia with t(5;12) chromosomal translocation
31. Chronic myeloproliferative diseases with t(5;12) and a PDGFRB fusion gene: Complete cytogenetic remissions on STI571
32. Molecular evidence for efficacy of STI-571 in chronic myelomonocytic leukemia (CMML) with a platelet-derived growth factor-β-receptor (PDGF-β-R) fusion oncogene
33. New insights into tumor suppression: PTEN suppresses tumor formation by restraining the phosphoinositide 3-kinase/AKT pathway
34. The multiple roles of PTEN in tumor suppression
35. PKB/Akt: Connecting phosphoinositide 3-kinase to cell survival and beyond
36. Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR
37. An inhibitor of mTOR reduces neoplasia and normalizes p70/S6 kinase activity in Pten+/- mice